Daiichi Sankyo (OTCMKTS:DSNKY) Sees Unusually-High Trading Volume – Here’s What Happened

Shares of Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) saw strong trading volume on Wednesday. 804,812 shares were traded during mid-day trading, an increase of 164% from the average daily volume of 304,809 shares. The stock last traded at $18.80 and had previously closed at $18.15.

Analyst Upgrades and Downgrades

DSNKY has been the subject of a number of recent analyst reports. Jefferies Financial Group lowered shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. Zacks Research lowered shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce”.

Daiichi Sankyo Stock Performance

The company’s 50-day moving average price is $17.77 and its 200 day moving average price is $17.63. The stock has a market capitalization of $35.04 billion, a PE ratio of 19.19, a PEG ratio of 2.08 and a beta of -0.10. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.96 and a current ratio of 2.92.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its quarterly earnings results on Friday, October 30th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.08. Daiichi Sankyo had a net margin of 12.13% and a return on equity of 16.31%. The company had revenue of $3.77 billion during the quarter, compared to the consensus estimate of $3.58 billion. On average, equities research analysts expect that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.87 earnings per share for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.

Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.